Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $1.44 EPS

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($2.77) EPS for the quarter, topping analysts' consensus estimates of ($4.21) by $1.44, Zacks reports. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Stock Up 2.3%

KPTI traded up $0.14 on Monday, hitting $6.15. The company's stock had a trading volume of 53,865 shares, compared to its average volume of 107,196. The company's 50 day simple moving average is $5.52 and its 200-day simple moving average is $8.94. The firm has a market cap of $52.71 million, a P/E ratio of -6.03 and a beta of 0.33. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $17.85.

Analysts Set New Price Targets

KPTI has been the topic of a number of research analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Finally, HC Wainwright lifted their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $57.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.